Posts With Tag lung cancer treatment

Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.

AstraZeneca's Imfinzi receives EU approval as the first immunotherapy for LS-SCLC, showing significant survival benefits. This landmark decision highlights advancements in cancer care.

Explore AstraZeneca's recent MAA withdrawal for datopotamab deruxtecan, ongoing trials, and strategies in advancing lung cancer therapies.